Cellectar Biosciences (NASDAQ:CLRB) CEO James V. Caruso Sells 34,000 Shares

Cellectar Biosciences (NASDAQ:CLRB) CEO James V. Caruso sold 34,000 shares of the company’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $1.20, for a total transaction of $40,800.00. Following the sale, the chief executive officer now owns 213,548 shares of the company’s stock, valued at approximately $256,257.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of CLRB stock traded up $0.02 on Friday, hitting $1.17. The stock had a trading volume of 166,639 shares, compared to its average volume of 358,812. The firm has a market capitalization of $20.34, a price-to-earnings ratio of -1.09 and a beta of 0.75. Cellectar Biosciences has a twelve month low of $1.03 and a twelve month high of $2.25.

How to Become a New Pot Stock Millionaire

Cellectar Biosciences (NASDAQ:CLRB) last announced its earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11). sell-side analysts predict that Cellectar Biosciences will post -0.71 earnings per share for the current year.

An institutional investor recently raised its position in Cellectar Biosciences stock. Vanguard Group Inc. grew its holdings in shares of Cellectar Biosciences (NASDAQ:CLRB) by 31.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,208 shares of the biopharmaceutical company’s stock after buying an additional 35,482 shares during the quarter. Vanguard Group Inc. owned approximately 1.09% of Cellectar Biosciences worth $240,000 at the end of the most recent reporting period. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Cellectar Biosciences from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine raised shares of Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

TRADEMARK VIOLATION WARNING: “Cellectar Biosciences (NASDAQ:CLRB) CEO James V. Caruso Sells 34,000 Shares” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/insider-selling-cellectar-biosciences-inc-clrb-ceo-sells-40800-00-in-stock.html.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease.

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply